Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates

Posted by Leanne Kodsman on

Normal Single Donor Human Plasma from Innovative Research was recently used in the following study:

Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates

Rolf W. Sparidans, Wenlong Li, Alfred H. Schinkel, Jan H.M. Schellens, Jos H. Beijnen
Journal of Pharmaceutical and Biomedical Analysis, August 2018

" ... Several second and third generation ALK inhibitors have been introduced in recent years. A bioanalytical assay for simultaneous quantification of alectinib, brigatinib, and lorlatinib was developed and validated for human plasma. The method was also partially validated for diluted mouse plasma and tissue homogenates of brain, liver, kidney, and spleen ... plasma of individual humans was provided by Innovative Research (Novi, MI, USA). "

Related products available from Innovative Research also include:


Share this post


Related Posts

Effect of CYP2C9 Polymorphisms on the Pharmacokinetics of Indomethacin During Pregnancy
Pooled Normal Human Plasma from Innovative Research was recently used in the following ...
Read the Article
Enzymatic Synthesis, Characterization and Biocompatibility Studies of Cellulose Nanoparticles from Cotton Fibers
Cellulase from Innovative Research was recently used in the following study: Enzyma...
Read the Article

← Older Post Newer Post →